GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cocrystal Pharma Inc (NAS:COCP) » Definitions » EBIT

COCP (Cocrystal Pharma) EBIT : $-20.31 Mil (TTM As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cocrystal Pharma EBIT?

Cocrystal Pharma's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-5.04 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-20.31 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cocrystal Pharma's annualized ROC % for the quarter that ended in Sep. 2024 was -844.73%. Cocrystal Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -1,052.61%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cocrystal Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -261.17%.


Cocrystal Pharma EBIT Historical Data

The historical data trend for Cocrystal Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cocrystal Pharma EBIT Chart

Cocrystal Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -48.15 -9.64 -14.18 -18.14 -21.16

Cocrystal Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.04 -5.67 -4.16 -5.45 -5.04

Competitive Comparison of Cocrystal Pharma's EBIT

For the Biotechnology subindustry, Cocrystal Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cocrystal Pharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cocrystal Pharma's EV-to-EBIT falls into.



Cocrystal Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cocrystal Pharma  (NAS:COCP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cocrystal Pharma's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-20.168 * ( 1 - 0% )/( (2.32 + 2.455)/ 2 )
=-20.168/2.3875
=-844.73 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Cocrystal Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-20.168/( ( (1.884 + max(-1.963, 0)) + (1.948 + max(-1.071, 0)) )/ 2 )
=-20.168/( ( 1.884 + 1.948 )/ 2 )
=-20.168/1.916
=-1,052.61 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.44) - (2.247 + 0 + 0.156)
=-1.963

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.584) - (1.47 + 0 + 0.185)
=-1.071

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cocrystal Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-20.314/7.778
=-261.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cocrystal Pharma EBIT Related Terms

Thank you for viewing the detailed overview of Cocrystal Pharma's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cocrystal Pharma Business Description

Traded in Other Exchanges
Address
19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Executives
Fred Hassan director C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Frost Phillip Md Et Al director, 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Raymond F Schinazi director, 10 percent owner 1860 MONTREAL ROAD, TUCKER GA 30084
Anthony J Japour director 19805 N. CREEK PARKWAY, BOTHELL WA 98011
Todd R. Brady director 19805 N. CREEK PARKWAY, BOTHELL WA 98011
James Joseph Martin officer: Interim CFO 4400 BISCAYNE BLVD, SUITE # 670, MIAMI FL 33157
Curtis Dale officer: INTERIM CFO 1860 MONTREAL ROAD, TUCKER GA 30084
Douglas L Mayers officer: CHIEF MEDICAL OFFICER C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Walt Addison Linscott officer: GENERAL COUNSEL AND SECRETARY 1860 MONTREAL ROAD, TUCKER GA 30084
Jeffrey A Meckler director 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
David S Block director
Hsiao Jane Ph D director 4400 BISCAYNE BLVD, MIAMI FL 33137
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Roger D. Kornberg director 345 WALSH ROAD, ATHERTON CA 94027